Planchard, Pegram Review Evidence for Samsung Bioepis Biosimilars
Biosimilars from Samsung Bioepis have demonstrated equivalency in clinical trial and real world settings, according to 2 prominent cancer specialists.
PrestigePharma Reports Positive PK Data for Bevacizumab Candidate
Singapore-based PrestigePharma presents fresh equivalency data supporting its case for regulatory approval of HD201.
Positive Equivalency Data for a Trio of Biosimilars Are Reported
Positive results emerging on oncology biosimilars will be presented at the European Society for Medical Oncology Virtual Congress 2020 this week .
Samsung Bioepis Reports Positive Phase 3 Results for Aybintio
Samsung Bioepis' bevacizumab biosimilar demonstrates equivalence in analyses to be presented at the European Society for Medical Oncology Virtual Congress 2020.
